The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

Overview of the Migraine Drugs MarketThe global Migraine Drugs Market is valued at $6.37 billion in 2024 and is projected to ...

Medtronic said Monday the U.S. Food and Drug Administration has approved an adaptive brain-stimulation device as a treatment ...

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for ...

The study will evaluate Sinaptica’s SinaptiStim in delivering simultaneous transcranial magnetic and alternating current ...

DARPA's latest program, RESTORE, aims to supercharge sleep deprived soldiers on as little as three hours of rest.

Primary safety endpoint met - No serious adverse events reported over 3-monthsRobust device performance - No device failure reported over 3-months Synergia Medical announces that its NAO.VNS device ...

The NaviFUS system uses transcranial focused ultrasound and therapeutic guidance tracking for drug delivery and neuromodulation, offering new hope for patients with brain cancer and drug-resistant ...